Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215514 · ClinicalTrials.gov registry record · Early Phase 1
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT00215514 is a Early Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00215514, a Early Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion 5-fluorouracil chemotherapy given along with radiation therapy.
Interventions
- DRUG Cisplatin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Epirubicin
- PROCEDURE Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-09 |
| Est. Completion | 2014-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215514
The ClinicalTrials.gov registry entry for NCT00215514 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00215514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00215514 about?
NCT00215514 is a clinical study titled "Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma". The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion 5-fluorouracil chemotherapy given along with radiation therapy.
What is the current status of trial NCT00215514?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2000-09. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00215514?
The interventions under investigation include: Cisplatin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Epirubicin (DRUG), Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00215514?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.